ey0016.11-9 | Metabolic Signaling | ESPEYB16
AS Wedell-Neergaard
, L Lang Lehrskov
, RH Christensen
, GE Legaard
, E Dorph
, MK Larsen
, N Launbo
, SR Fagerlind
, SK Seide
, S Nymand
, M Ball
, N Vinum
, CN Dahl
, M Henneberg
, M Ried-Larsen
, JD Nybing
, R Christensen
, JB Rosenmeier
, K Karstoft
, BK Pedersen
, H Ellingsgaard
, R Krogh-Madsen
To read the full abstract: Cell Metab 2019; 29(4): 84455This randomized, placebo-controlled, double blind trial showed that IL-6 is necessary for exercise-mediated loss of visceral adipose tissue mass. 53 participants (men and women) received either tocilizumab, an IL-6 signaling blocker (intervention group) or placebo (control group), every four weeks, in a ...